Stockscreener 앱 받기
6.12
5.06%
-0.31
전일 마감가:
$6.43
열려 있는:
$6.64
하루 거래량:
1.52M
Relative Volume:
0.74
시가총액:
$447.07M
수익:
$161.10M
순이익/손실:
$-308.60M
주가수익비율:
-1.3105
EPS:
-4.67
순현금흐름:
$-259.90M
1주 성능:
-17.95%
1개월 성능:
-21.64%
6개월 성능:
-67.36%
1년 성능:
-74.95%
1일 변동 폭
$6.07
$6.64
1주일 범위
$6.07
$7.83
52주 변동 폭
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
ARVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.125 | 555.46M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.78 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.99 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.97 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.10 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.30 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-02 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-03-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - Stocktwits
Arvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Guggenheim lowers Arvinas stock price target to $15 on partnership concerns - Investing.com
Insider Sellers Might Regret Selling Arvinas Shares at a Lower Price Than Current Market Value - simplywall.st
Arvinas Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by XTX Topco Ltd - MarketBeat
Federated Hermes Inc. Purchases 933,183 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Reports Q2 2025 Financials and Drug Developments - TipRanks
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas Q2 2025 Earnings Call Transcript - MarketBeat
ARVINAS, INC. SEC 10-Q Report - TradingView
Earnings call transcript: Arvinas Q2 2025 results show revenue miss, stock drops - Investing.com
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Arvinas earnings beat by $0.10, revenue fell short of estimates - Investing.com Canada
Arvinas Inc (ARVN) Q2 2025 Earnings: EPS Beats Estimates at -$0. - GuruFocus
What To Expect From Arvinas Inc (ARVN) Q2 2025 Earnings - Yahoo Finance
What drives Arvinas Inc. stock priceFind market-beating stocks for your portfolio - Jammu Links News
What are the technical indicators suggesting about Arvinas Inc.Unlock the power of real-time market data - Jammu Links News
Arvinas (NASDAQ:ARVN) Stock Price Up 8.6%Time to Buy? - MarketBeat
What are the latest earnings results for Arvinas Inc.High-impact stock picks - Jammu Links News
Is Arvinas Inc. a good long term investmentBuild wealth faster with consistent investment plans - Jammu Links News
What is Arvinas Inc. company’s growth strategyAchieve rapid portfolio growth with smart picks - Jammu Links News
What is the dividend policy of Arvinas Inc. stockCapitalize on proven investment strategies - Jammu Links News
How does Arvinas Inc. generate profit in a changing economyGet real-time alerts on high-potential stocks - Jammu Links News
What catalysts could drive Arvinas Inc. stock higher in 2025Tremendous portfolio expansion - Jammu Links News
Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Boosted by Monaco Asset Management SAM - MarketBeat
What makes Arvinas Inc. stock price move sharplyUnlock powerful insights from market experts - Jammu Links News
Does Arvinas Inc. stock perform well during market downturnsCapitalize on momentum-driven stocks - Jammu Links News
Arvinas Inc. Could See a Relief Rally From SupportHigh Return Stock Focus With Safety Emphasized - metal.it
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 - 富途牛牛
Should I hold or sell Arvinas Inc. stock in 2025Earnings Report Opportunities To Watch Now - Jammu Links News
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Yahoo Finance
Investors in Arvinas (NASDAQ:ARVN) have unfortunately lost 86% over the last three years - Yahoo Finance
Is Arvinas Inc. the Top Chart Pick This WeekBig Return Stock Tips - beatles.ru
Arvinas, Inc. to Host Q2 2025 Financial Results and Corporate Update Webcast on August 6, 2025 - Quiver Quantitative
Protein Degradation Pioneer Arvinas Sets Q2 2025 Earnings Report DateKey Details Inside - Stock Titan
Using data filters to optimize entry into Arvinas Inc.News Based Entry Opportunity Alerts Detected - metal.it
Leerink Partners Reaffirms Hold Rating on Arvinas Holding Company Amid Mixed Analyst Sentiment - AInvest
Watch for Bullish Crossover in Arvinas Inc.Risk Adjusted Technical Entry Plan Gains Followers - metal.it
Published on: 2025-07-29 21:05:33 - metal.it
Technical Bounce Expected in Arvinas Inc. Next WeekTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Published on: 2025-07-29 03:00:57 - metal.it
ESR1 Mutated Metastatic Breast Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Sun Pharma, Zenopharm, Arvinas, Sermonix Pharma, H3 Biomedicine, Radius Pharma - Barchart.com
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.28%
2.25%
자본화:
|
볼륨(24시간):